Amylin Submits Once-Weekly Byetta After Shedding 200 Sales Reps
This article was originally published in The Pink Sheet Daily
Executive Summary
Label with expanded language about thyroid cancer risk is expected.
You may also be interested in...
Byetta Needs More Studies To Determine Pancreatitis Risks, FDA Says
The previously undisclosed requirements are a setback to Amylin and Lilly, which jointly market the drug and plan a once-weekly version.
Byetta Needs More Studies To Determine Pancreatitis Risks, FDA Says
The previously undisclosed requirements are a setback to Amylin and Lilly, which jointly market the drug and plan a once-weekly version.
FDA's Handling Of Byetta Pancreatitis Risk Could Bode Well For Other Diabetes Drugs
Amylin's Byetta cleared for first-line use without a black box stigma, but sales may still not get a lift.